Artivion acquires Endospan for US$135M upfront to secure FDA-approved stent platform

USA—Artivion has completed its acquisition of Israeli medical device company Endospan for US$135 million, following US Food and Drug Administration (FDA) approval of the NEXUS aortic arch stent graft system.

The transaction activates a pre-agreed option established in 2019, which granted Artivion the right to acquire Endospan upon regulatory clearance in the United States.

In addition, the agreement includes contingent payments of up to US$200 million tied to NEXUS’s commercial performance in the US market over the next two years.

Strategic deal structure anchored on regulatory approval

The acquisition reflects a long-term strategic collaboration between the two companies, with Artivion already serving as the exclusive distributor of NEXUS across Europe, the Middle East, and Africa since 2019.

By exercising the purchase option after FDA approval on 7 April, Artivion consolidates control over a technology it has supported through its global commercial network.

The deal structure links an upfront payment to performance-based milestones, aligning both companies’ interests around market expansion and adoption.

NEXUS system targets complex aortic conditions

The NEXUS system is designed for high-risk patients suffering from complex aortic arch diseases, including chronic aortic dissections and aortic arch syndrome.

The aorta, the body’s largest blood vessel, carries oxygenated blood from the left side of the heart to the rest of the body, making conditions affecting it life-threatening and technically challenging to treat.

Despite affecting more than 120,000 patients annually across the United States and Europe, only about a quarter of cases are diagnosed or treated, largely due to surgical risk limitations and anatomical complexity.

Expanding aortic innovation portfolio

Artivion CEO Pat Mackin said the acquisition completes what he described as the company’s “three-pronged aortic arch portfolio,” which already includes the Arcevo LSA stent graft and the AMDS prosthesis for DeBakey Type I aortic dissection with malperfusion.

He added that integrating Endospan brings additional next-generation technologies under development, which are expected to reinforce Artivion’s position in the aortic treatment market over time.

In a recent corporate update, the company also reiterated its focus on expanding minimally invasive and hybrid aortic solutions and highlighted continued investment in its cardiovascular innovation pipeline.

Clinical perspective and market opportunity

Endospan CEO Kevin Mayberry described FDA approval of NEXUS as a pivotal development for aortic surgeons, particularly those managing complex ascending and arch pathologies.

He noted that combining Endospan’s technology with Artivion’s established expertise in open, endovascular, and hybrid procedures positions the system within a broader multidisciplinary treatment framework.

Aortic arch syndrome involves the major arteries branching from the aorta, which can restrict blood flow to the vital organs and tissues they supply.

As demand for less invasive and more adaptable treatment options continues to grow, both companies expect broader clinical adoption of advanced stent graft technologies to reshape the management of high-risk cardiovascular patients.